MedTrace Logo

New Pathophysiological Pathways Involved in Iron Metabolism Disorder in Heart Failure

NCT05000853 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 210

Last updated 2022-12-13

No results posted yet for this study

Summary

The aim of our study is to understand the biological pathways involved in the occurrence of IDy in patients with HF since ID is very common and supposes a negative impact in terms of clinical outcomes in these patients. In this context, a deeper understanding of the mechanisms involved in the development of ID in these patients and the impact on the altered biological pathways after iron replenishment will pave the way for an improvement and simplification of the preventive strategies in patients with HF.

Conditions

Interventions

DRUG

Iron Carboxymaltose

Iron supplementation when is needed according to usual care

Sponsors & Collaborators

  • Hospital Universitari de Bellvitge

    lead OTHER

Principal Investigators

  • Josep Comin Colet, MD, PhD · Bellvitge Biomedical Research Institute (IDIBELL) - Hospital Universitari de Bellvitge

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2023-07-01
Completion
2023-08-01
FDA Drug
Yes

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05000853 on ClinicalTrials.gov